Two recombinant variants are commercially available:
Bioactivity: Recombinant TGFB2 inhibits IL-4-induced proliferation in HT-2 mouse T-cells with an ED₅₀ of 0.025–0.25 ng/mL .
Cross-Species Reactivity: Shares 97% amino acid identity with rodent TGFB2 and 100% identity with porcine, bovine, and canine homologs, enabling cross-species experimental use .
Signaling Mechanism: Binds to TGF-β receptor II (TβRII) and betaglycan (TβRIII), activating Smad-dependent and Smad-independent pathways .
Recombinant TGFB2 is utilized in:
Cell Culture Studies: Modulates epithelial-mesenchymal transition and immune cell function .
Bioassays: Quantifies activity via mink lung epithelial (Mv1Lu) cell proliferation inhibition (ED₅₀ < 40 ng/mL) .
Disease Models: Investigated in fibrosis, glaucoma, and cancer due to its role in tissue remodeling .
Reconstitution: Requires sterile 4 mM HCl with carrier proteins (e.g., BSA) for enhanced stability .
Freeze-Thaw: Avoid repeated cycles; store working aliquots at 4°C for ≤7 days .